TrialBlood advances2024

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.

Pier Luigi Zinzani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.